Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts
The research carried out by the hospital and departments of theuniversity of Aachen and the Universities of Munich and Regensburg, Germany,analysed the osteogenic potential of Fortoss Vital for maxillary sinus flooraugmentation on a 61 year old female. The samples taken from the graft siteat 6 months, showed the negative surface charge of Fortoss Vital hadaccelerated the bone formation cascade and rapidly produced mature lamellarbone formation with marrow cavities. The bone density at the graft site wasshown to be denser than the original bone matrix of the posterior maxillaryregion. Evidence also confirmed the complete resorption of Fortoss Vital.
Fortoss Vital is a unique, bi-phasic calcium composite bone graftmaterial having a negative surface charge which attracts the key proteins andcells for rapid osteogenesis and bone repair. Fortoss Vital is fully resorbedby osteoclastic processes and replaced by bone.
Biocomposites' Managing Director Stephen Bratt said, "This independentclinical data in a maxillofacial indication, corroborates similar orthopaedicstudies confirming that Biocomposites' ZPC technology, with a unique surfacechemistry accelerates bone growth.
About the company:
Biocomposites is a privately held, leading developer, manufacturer anddistributor of synthetic, tissue regeneration products. Since 1997, thecompany has developed a broad range of products that addresses the clinicaland economic needs of medical specialties in orthopaedics and dentistry.Research, manufacturing, sales and marketing are directed from the company'sheadquarters in Keele, Staffordshire, UK. Biocomposites also has twosubsidiary companies, based in Shanghai, P.R.China and Wilmington, NorthCarolina, USA.
Fortoss Vital(R) and Biocomposites(R) The Next Regeneration(TM) areregistered trademarks of Biocomposites Ltd.
Smeets et al. " A new biphasic osteoinductive calcium composite materialwith a negative Zeta potential for bone augmentation." Head & face Medicine2009, 5:13 doi:10.1186/1746-160X-5-13.
SOURCE Biocomposites Ltd
You May Also Like